Company: PSTV
Filing Date: 2025-11-17
Form Type: 8-K
Source: 0001193125-25-283935
Chunk: 0

Company: PLUS THERAPEUTICS, INC.
Filing Date: 2025-11-17
Form: 8-K
Item: Item 7.01
Chunk 0
---
Item 7.01.      Regulation FD Disclosure.  

On November 17, 2025, Plus Therapeutics, Inc. (the “ Company”) issued a press release announcing that it had received an additional180-dayextension period from the Nasdaq Listing Qualifications Department (the “ Nasdaq Staff”) to regain compliance with the $1.00 minimum bid price bid requirement set forth in Nasdaq Listing Rule 5550(a)(2) (the “ Minimum Bid Price Requirement”), discussed in more detail in Item 8.01 below.

The press release is furnished herewith as Exhibit 99.1 and incorporated by reference herein. The information contained in the press release is being furnished and shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act”), or otherwise subject to the liability of that Section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.